SCHEMBL3771815

SCHEMBL3771815

COc1ccc(-c2cccc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)c2)cc1F

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 4/20 0.43
TDP1 Q9NUW8 2/20 0.42
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPK1 P28482 2/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RORC P51449 1/20 0.40
POLB P06746 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774486 0.92 ALDH1A1 (0.46) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL3773843 0.86 MEN1 (0.51) TSHRMEN1KMT2AALDH1A1KDM4E
SCHEMBL3760962 0.84 ALDH1A1 (0.60) TSHRMEN1KMT2AALDH1A1KDM4E
SCHEMBL3773763 0.83 HSD17B10 (0.53) TSHRMEN1KMT2AALDH1A1KDM4E
SCHEMBL3773827 0.83 ALDH1A1 (0.44) ALDH1A1KDM4EMAPTTDP1LMNA
SCHEMBL3765124 0.83 TSHR (0.59) TSHRMEN1KMT2AALDH1A1KDM4E
SCHEMBL3765294 0.83 ALDH1A1 (0.51) TSHRMEN1KMT2AALDH1A1KDM4E
SCHEMBL3779268 0.83 MEN1 (0.49) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL3774746 0.82 LMNA (0.46) TSHRALDH1A1KDM4EMAPTTDP1
SCHEMBL3765482 0.82 HSD17B10 (0.45) TSHRALDH1A1KDM4EMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 TSHR 436/4885MEN1 3270/4885KMT2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.